{"id":"W3133799417","doi":"10.1080/10428194.2021.1889536","title":"The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study","year":2021,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Dasatinib; Myeloid leukemia; Medicine; Nivolumab; Nilotinib; Oncology; Internal medicine; Leukemia; Immunotherapy; Cancer; Imatinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008653371,0.002373576,0.003901492,0.0006887115,0.0007593598,0.0003333809,0.000822962,0.002347246,0.00006202679],"category_scores_gemma":[0.0006474718,0.001787667,0.000482318,0.001492619,0.001069273,0.00044325,0.0006374434,0.001559187,0.00002488688],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.0708144,"about_ca_system_score_gemma":0.02217738,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01598129,"about_ca_topic_score_gemma":0.002029151,"domain_scores_codex":[0.9874582,0.001043813,0.003602905,0.003474836,0.002338301,0.002081889],"domain_scores_gemma":[0.9905841,0.002719428,0.002196741,0.00329187,0.0005986927,0.0006091887],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.11964,0.008575644,0.09055955,0.002803934,0.01096802,0.01201472,0.01518776,0.0004255697,0.0002582589,0.00002225757,0.07212713,0.6674171],"study_design_scores_gemma":[0.4714901,0.00710686,0.4635589,0.003705134,0.003279295,0.000303531,0.0006178853,0.003069235,0.0002684146,0.00001698104,0.04471993,0.001863724],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.982565,0.00537205,0.000009651316,0.002631398,0.0003909523,0.006784567,0.001163235,0.000251192,0.0008319186],"genre_scores_gemma":[0.9696319,0.00340488,0.0002468474,0.006799926,0.001718737,0.0004908359,0.01423389,0.0005694901,0.00290354],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6655534,"threshold_uncertainty_score":0.9989479,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01104437647212379,"score_gpt":0.2445490745034217,"score_spread":0.2335046980312979,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}